Most AI biomarker models never reach a patient, and the gap is usually evidence rather than algorithms. Here is the…
Enrichment, stratified, basket, umbrella and platform designs compared, with the trials that set the template and the screening, assay and…
A companion diagnostic gates access to a drug; a complementary diagnostic informs the decision without being required. We set out…
Dates for the 2027 spring cancer research meeting, the six IO and biomarker themes oncology teams should plan around, and…
A preview of eleven speakers on the ImmunoMark Summit London 2027 agenda, from myeloid checkpoints and logic-gated CAR T to…
ADC plus checkpoint inhibitor combinations are moving into first-line care, but target expression has not predicted benefit for TROP2 ADCs.…
Early March 2027 puts IO and biomarker science (ImmunoMark London, 3–4 March) and ADC development in London in the same…
A preview of the speakers and confirmed sessions at ImmunoMark Summit San Diego (10–11 February 2027), taken directly from the…
How tumour-informed and tumour-agnostic MRD testing, early ctDNA molecular response and serial surveillance are reshaping checkpoint inhibitor trials, and what…
Tebentafusp and tarlatamab have shown T cell engagers can extend survival in solid tumours. Here is where targets, toxicity management…
300+ senior leaders. Two streams. One agenda: advancing precision oncology.